Why Is CLOVER HEALTH INVTS A (CLOV) Stock Moving Today?
By the Top Tier Newswire AI Desk · September 11, 2026 at 12:05 AM ET · reviewed against 3 wire stories
CLOVER HEALTH INVTS A (CLOV) is drawing unusual attention today. Our newswire has captured 3 stories on CLOV across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
CLOV stock is up 8.53% to $4.71 in today’s session, driven by a new Buy initiation from Deutsche Bank and a recent sales guidance raise. The stock has gained momentum following a series of positive developments, including upwardly revised revenue forecasts and a strong intraday price trend. Coverage from The Fly and other outlets has highlighted the stock’s performance, reflecting investor interest.
What Happened
Deutsche Bank initiated Clover Health with a Buy rating, signaling a shift in analyst sentiment for the unprofitable but high-growth company. This followed a recent update from the company, which raised its FY2026 sales guidance to a range of $2.920B to $3.000B, exceeding the $2.910B consensus estimate. The stock has responded positively, rising nearly 9% in two of the last three sessions and printing 12 fresh 52-week highs on September 10. The company’s revenue growth remains strong at 54.0% year to date, despite a net margin of -0.7% and an unprofitable EPS of -0.04.
What The Data Shows
Over the past eight trading sessions, CLOV has risen 12.4% from $4.20 to $4.72. Insider transactions have been largely sell-heavy, with 16 reported sales totaling $3.1 million in the last 90 days. The most recent sale occurred on August 17 by the interim CFO. The stock’s beta of 2.48 indicates it is more volatile than the broader market. Despite recent gains, the stock remains within its 52-week range of $1.58 to $5.59.
What To Watch
Investors should monitor the breadth of coverage for further analyst commentary and any upcoming corporate developments. The company’s ability to meet or exceed its revised sales guidance could influence future stock performance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CLOV · Sep 11 session (5-min) · +2.34% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 3 stories · 53/100 neutral
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
6h agoSEC 8-KNEUTRAL 50General
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) files 8-K
Filed: 2026-09-24 AccNo: 0001801170-26-000229 Size: 157 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
6h agoStockTitanBULLISH 55General
Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D. to Its Board of Directors
The appointments fill two disclosed vacancies and bring the board to nine. Torricelli joins its Audit Committee; Miller joins its Clinical Committee.
6h agoBusiness InsiderBULLISH 55General
UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. to Its Board of Directors
WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D.
Frequently asked questions
Why is CLOV stock moving today?
CLOVER HEALTH INVTS A (CLOV) is drawing unusual attention today. Our newswire has captured 3 stories on CLOV across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100). The most recent driver: "CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) files 8-K" (SEC 8-K).
Is CLOV a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of CLOV coverage reads 53/100 over 3 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →